Evidence map›Paper›PMID 23140417›Full record

Trial reportNutrition journal2012

Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women.

Toshiro Sato, Leon J Schurgers, Kazuhiro Uenishi

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrition journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05081960 (Evaluating the Vitamin K2 Status of Calcium-based Stone Formers), which is not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05081960 completednot on this mapstarted 2022, after this paper: background citation

Evaluating the Vitamin K2 Status of Calcium-based Stone Formers

TypeobservationalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2022 to 2025Enrolled60ConditionsKidney Calculi, Calcium Oxalate Kidney Stones, Vitamin K 2, Human
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Comparison of cheese with and withoutJournal of the International Society of Sports Nutrition · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
    Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Supplements for bone health.Archives of endocrinology and metabolism · 2025
    Review
  14. Metabolic Engineering Strategy forFoods (Basel, Switzerland) · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Toshiro SatoFine Chemical Laboratory, J-OIL MILLS, INC, 1746 Nakashinden, Fukuroi-city, Shizuoka, 437-1111, Japan. toshiro.sato@j-oil.com
Leon J Schurgers
Kazuhiro Uenishi
Kagawa Nutrition University · JPMaastricht University · NLThe Nisshin OilliO Group (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin K₂ contributes to bone and cardiovascular health. Therefore, two vitamin K₂ homologues, menaquinone-4 (MK-4) and menaquinone-7 (MK-7), have been used as nutrients by the food industry and as nutritional supplements to support bone and cardiovascular health. However, little is known about the bioavailability of nutritional MK-4. To investigate MK-4 and MK-7 bioavailability, nutritional doses were administered to healthy Japanese women.

findingsSingle dose administration of MK-4 (420 μg; 945 nmol) or MK-7 (420 μg; 647 nmol) was given in the morning together with standardized breakfast. MK-7 was well absorbed and reached maximal serum level at 6 h after intake and was detected up to 48 h after intake. MK-4 was not detectable in the serum of all subjects at any time point. Consecutive administration of MK-4 (60 μg; 135 nmol) or MK-7 (60 μg; 92 nmol) for 7 days demonstrated that MK-4 supplementation did not increase serum MK-4 levels. However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects.

conclusionsWe conclude that MK-4 present in food does not contribute to the vitamin K status as measured by serum vitamin K levels. MK-7, however significantly increases serum MK-7 levels and therefore may be of particular importance for extrahepatic tissues.

Indexed as

Dietary SupplementsFood, FortifiedIntestinal AbsorptionAdultBone Density Conservation AgentsBreakfastCardiovascular AgentsChromatography, High Pressure LiquidFemaleHumansKineticsLimit of DetectionNutritive ValueSpectrometry, FluorescenceVitamin K 2Young AdultBone Density Conservation AgentsCardiovascular Agentsmenaquinone 7menatetrenoneVitamin K 2

Identifiers

PMID23140417
PMCPMC3502319
OpenAlexW1998616007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.